免疫检查点抑制剂治疗中静脉与动脉血栓栓塞的发生率、危险因素及结局
该回顾性研究纳入2015至2018年在维也纳医科大学接受免疫检查点抑制剂治疗的672例癌症患者,中位随访8.5个月,观察47例静脉血栓栓塞(VTE)和9例动脉血栓栓塞(ATE),VTE累积发生率12.9%,ATE为1.8%,VTE发生与死亡率增加相关(转移风险比3.09),VTE病史可预测VTE发生(SHR 3.69)。
要点
- 免疫检查点抑制剂治疗患者VTE累积发生率为12.9%,ATE为1.8%。
- VTE发生与死亡率增加独立相关(转移风险比3.09,95%CI 2.07-4.60)。
- VTE病史是VTE发生的显著预测因素(SHR 3.69,95%CI 2.00-6.81)。
核心结论
- 接受免疫检查点抑制剂治疗的癌症患者血栓栓塞风险高,尤其是VTE。
- VTE的发生与死亡率增加相关。
研究设计与样本
- 回顾性队列研究,利用药房记录识别2015至2018年维也纳医科大学接受免疫检查点抑制剂治疗的患者672例。
- 最常见肿瘤类型为黑色素瘤(30.4%)和非小细胞肺癌(24.1%),86%为IV期疾病。
- 通过病历回顾筛查VTE和/或ATE,采用竞争风险分析估计累积发生率和组间差异,采用多状态模型研究VTE/ATE对死亡率的影响。
主要发现
- 中位随访8.5个月,观察到47例VTE和9例ATE。
- VTE累积发生率为12.9%(95%CI 8.2-18.5),ATE累积发生率为1.8%(95%CI 0.7-3.6)。
- VTE发生与死亡率增加相关(转移风险比3.09,95%CI 2.07-4.60)。
- VTE病史预测VTE发生(SHR 3.69,95%CI 2.00-6.81),远处转移与VTE风险无显著相关(SHR 1.71,95%CI 0.62-4.73)。
- 未观察到VTE与ECOG体能状态、Charlson合并症指数或Khorana评分相关,不同肿瘤类型和检查点抑制剂之间VTE发生率相当。
临床怎么用
- 对接受免疫检查点抑制剂治疗的癌症患者,尤其有VTE病史者,应关注血栓栓塞风险。
- 发生VTE可能提示死亡风险增加,需加强监测与管理。
局限性
- 回顾性单中心研究,样本来自维也纳医科大学,结论外推需谨慎。
- 中位随访时间较短(8.5个月),可能低估远期血栓事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) associated with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of VTE/ATE in patients with cancer treated with immune checkpoint inhibitors, explore clinical impact, and investigate potential clinical risk factors. Patients treated with immune checkpoint inhibitors at the Medical University of Vienna from 2015 to 2018 were identified using in-house pharmacy records (n = 672; most frequent entities: 30.4% melanoma, 24.1% non-small cell lung cancer; 86% stage IV disease). A retrospective chart review was performed to screen for VTE and/or ATE. Cumulative incidences and between-group differences were estimated in competing-risk analysis. The impact of VTE/ATE on mortality was studied by multistate modelling. Over a median follow-up of 8.5 months, 47 VTEs and 9 ATEs were observed. Cumulative incidences of VTE and ATE were 12.9% (95% confidence interval [CI], 8.2-18.5) and 1.8% (95% CI, 0.7-3.6). Occurrence of VTE was associated with increased mortality (transition hazard ratio, 3.09; 95% CI, 2.07-4.60). History of VTE predicted VTE occurrence (subdistribution hazard ratio [SHR], 3.69; 95% CI, 2.00-6.81), and distant metastasis was nonsignificantly associated with VTE risk (SHR, 1.71; 95% CI, 0.62-4.73). No association of VTE with Eastern Cooperative Oncology Group performance status, Charlson comorbidity index, or Khorana score was observed, and rates of VTE were comparable between tumor types and checkpoint-inhibitory agents. In conclusion, patients with cancer under immune checkpoint inhibitor therapy are at high risk of thromboembolism, especially VTE. Furthermore, VTE occurrence was associated with increased mortality.
引用
- Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021. PMID: 33067632. doi:10.1182/blood.2020007878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。